GlassScriptPhysician profile
Mary E Martin
NPI 1316365745
$2,027.70
in general payments reported to CMS, 2019-2025
31 companies · $922 in 2025
The $922 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.07 · 2022: $82.77 · 2023: $318 · 2024: $686 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $175.86 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $174.78 | 2024-2025 | |
| Abbvie INC. | $147.08 | 2022-2025 | |
| Eisai INC. | $144.16 | 2025 | |
| Scpharmaceuticals INC. | $137.52 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $120.39 | 2024-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $118.86 | 2024-2025 | Verquvo |
| Boston Scientific Corporation | $113.87 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply, Vercise |
| Otsuka America Pharmaceutical, INC. | $94.91 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $80.66 | 2024-2025 | |
| Amgen INC. | $75.52 | 2024-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $73.16 | 2024 | |
| Biogen, INC. | $67.64 | 2025 | Vumerity, Tysabri |
| Cvrx, INC. | $62.88 | 2024-2025 | Barostim Neo System |
| Glaxosmithkline, LLC. | $58.33 | 2023-2024 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.86 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.96 | 2024 | Jardiance |
| Bridgebio Pharma, INC. | $30.84 | 2025 | Attruby |
| Novo Nordisk INC | $30.15 | 2022-2023 | |
| Abbott Laboratories | $28.14 | 2023 | Freestyle Libre 2 |
| Grifols USA, LLC | $25.87 | 2025 | Gamunex-C |
| Argenx US, INC. | $25.68 | 2025 | Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $24.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.59 | 2024 | Farxiga |
| Lilly USA, LLC | $19.50 | 2023 | Mounjaro |
| Horizon Therapeutics Plc | $19.07 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $17.72 | 2024 | Arcalyst |
| Astellas Pharma US INC | $16.03 | 2023 | Veozah |
| Philips North America LLC | $15.03 | 2024 | (Am5) Lead Management |
| Dexcom, INC. | $14.49 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $12.96 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.